LCM
CSTL icon

Legato Capital Management’s Castle Biosciences CSTL Stock Holding History

Legato Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,395
Closed -$277K – 582
2024
Q4 		$277K Sell
10,395
-15,890
-60% -$484K 0.04% 506
2024
Q3 		$750K Buy
26,285
+12,130
+86% +$309K 0.09% 368
2024
Q2 		$308K Buy
+14,155
New +$315K 0.04% 487
2023
Q2 		– Sell
-27,534
Closed -$626K – 585
2023
Q1 		$626K Buy
27,534
+9,038
+49% +$221K 0.11% 311
2022
Q4 		$435K Buy
+18,496
New +$429K 0.08% 374

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Legato Capital Management's CSTL Position: Q1 2025 in Review

Legato Capital Management sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 10,395 shares — an estimated $277K sold.

Legato Capital Management first reported a position in CSTL in Q4 2022 and held it in 5 quarters. The position peaked at $750K in Q3 2024. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

  • Legato Capital Management reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
  • Legato Capital Management sold 10,395 Castle Biosciences shares in Q1 2025, an estimated $277K.
  • Legato Capital Management first reported a position in Castle Biosciences in Q4 2022 and held it in 5 quarters.
  • Legato Capital Management's Castle Biosciences position peaked at $750K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Legato Capital Management's 13F filing for Q1 2025, filed 6 May 2025.